{"id":"ciprofloxacin-cotrimoxazole-trimethoprim-macrodantin","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Nausea"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"3-8","effect":"Headache"},{"rate":"1-3","effect":"Photosensitivity (ciprofloxacin)"},{"rate":"2-5","effect":"Rash"},{"rate":"0.5-1","effect":"Peripheral neuropathy (nitrofurantoin)"},{"rate":null,"effect":"Stevens-Johnson syndrome (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ciprofloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication. Cotrimoxazole (sulfamethoxazole-trimethoprim) is a sulfonamide-diaminopyrimidine combination that sequentially blocks bacterial folate synthesis. Nitrofurantoin (macrodantin) generates reactive oxygen species that damage bacterial DNA and proteins. Together, these agents provide broad-spectrum coverage against gram-positive and gram-negative bacteria.","oneSentence":"This is a combination of three distinct antibacterial agents that work through different mechanisms to inhibit bacterial growth and kill bacteria.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:43:29.721Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Urinary tract infections"},{"name":"Bacterial respiratory infections"},{"name":"Gastrointestinal infections"},{"name":"Skin and soft tissue infections"}]},"trialDetails":[{"nctId":"NCT05274672","phase":"PHASE4","title":"Role of Prophylactic Postoperative Antibiotics in HoLEP","status":"WITHDRAWN","sponsor":"Baylor Research Institute","startDate":"2023-03-01","conditions":"Benign Prostatic Hyperplasia, Urinary Tract Infections","enrollment":""},{"nctId":"NCT05726318","phase":"PHASE4","title":"Randomized Trial of Culture Directed Versus Empiric Antibiotics for Urinary Tract Infections in Older Women","status":"COMPLETED","sponsor":"Megan Bradley","startDate":"2023-02-17","conditions":"UTI","enrollment":70},{"nctId":"NCT02829060","phase":"NA","title":"Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2016-01","conditions":"Nephrolithiasis, Urinary Tract Infection (UTI), Sepsis","enrollment":330},{"nctId":"NCT06709196","phase":"PHASE4","title":"Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2025-01-07","conditions":"Cystectomy, Bladder Cancer Requiring Cystectomy, Postoperative Infections","enrollment":248},{"nctId":"NCT05519072","phase":"PHASE4","title":"Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA","status":"RECRUITING","sponsor":"Atlantic Health System","startDate":"2022-08-16","conditions":"Antibiotic Prophylaxis","enrollment":140},{"nctId":"NCT05719285","phase":"PHASE4","title":"Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2022-12-06","conditions":"Overactive Bladder, Overactive Bladder Syndrome, Urge Incontinence","enrollment":100},{"nctId":"NCT05384197","phase":"PHASE3","title":"Enhanced Versus Extended Preoperative Antibiotic Prophylaxis Regimens for Retrograde Intrarenal Surgery in High Infectious Risk Patients","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2022-05-01","conditions":"Renal Stone","enrollment":280},{"nctId":"NCT02375295","phase":"PHASE4","title":"Struvite Stones Antibiotic Study","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2015-03","conditions":"Kidney Stones","enrollment":28},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT01584765","phase":"","title":"Rechallenge, Potential Drug Induced Liver Injury (Kaiser)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-02","conditions":"Drug-induced Liver Injury","enrollment":1},{"nctId":"NCT01349738","phase":"","title":"Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants","status":"UNKNOWN","sponsor":"Rice, James C., M.D.","startDate":"2011-05","conditions":"Bacteriuria, Urinary Tract Infections, Asymptomatic Infections","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Keflex, Macrobid, co-trimoxazole"],"phase":"marketed","status":"active","brandName":"ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin","genericName":"ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin","companyName":"University of British Columbia","companyId":"university-of-british-columbia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination of three distinct antibacterial agents that work through different mechanisms to inhibit bacterial growth and kill bacteria. Used for Urinary tract infections, Bacterial respiratory infections, Gastrointestinal infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}